U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020

アメリカの全身麻酔薬市場:プロポフォール、ベンゾジアゼピン、ケタミン、メトヘキシタールナトリウム

◆タイトル:U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020
◆商品コード:MAM-PH-1174
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年7月24日
◆ページ数:127
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、アメリカの全身麻酔薬市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、市場シェア分析、種類別分析、投与経路別分析、サプライチェーン分析、市場規模及び予測、競争状況、関連企業分析などの情報をお届けいたします。

The report segments the U.S. general anesthesia drugs market on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.

Acquisitions was the most preferred strategy adopted by major industry players in order to increase their market shares and cater to unmet needs.
This report provides insights on the qualitative data, market size, growth of various segments and subsegments, and prominent players in this market. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market sizes and data on the growth of various segments in the industry. It focuses on emerging and high-growth segments, high-growth regions, and government initiatives. The report also provides a company profiles section, which comprises basic views on the key players in the U.S. general anesthesia drugs market and their product portfolios, developments, and strategies adopted to maintain and increase their market shares. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned three strategies (market penetration, competitive assessment, and market entry).

The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios of the top players in the U.S. general anesthesia drugs market. The report analyzes the U.S. general anesthesia drugs market by molecule and mode of administration.
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the U.S. general anesthesia drugs market
• Market Entry: Comprehensive information about business strategies for entering the U.S. general anesthesia drugs market

【レポートの目次】

1 Introduction (Page No. – 10)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Years Considered for the Study
1.3 Currency
1.4 Stakeholders

2 Research Methodology (Page No. – 12)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.2.2.1 Key Industry Insights
2.2.3 Assumptions for the Study

3 Market Overview (Page No. – 19)
3.1 Market Analysis
3.2 Market Size
3.2.1 Historical Market Trends, 2010–2014
3.2.2 Market Forecasts, 2015–2020

4 Distribution Structure (Page No. – 22)
4.1 U.S. Ketamine Market: Distribution Structure
4.2 U.S. Ketamine Market, 2010–2014
4.2.1 U.S. Ketamine Market, By Manufacturer
4.2.2 U.S. Ketamine Market, By Distribution Channel
4.2.2.1 Group Purchasing Organizations (GPOs)
4.2.2.2 Distributors
4.3 Major Legal Trends for Controlled Substances
4.3.1 Trends Associated With Manufacturing of Narcotics in the U.S.
4.3.1.1 Registration
4.3.1.2 Security
4.3.1.3 Labeling and Packaging
4.3.1.4 Inventory
4.3.1.5 Records
4.3.2 Trends Associated With Vendors of Narcotics in the U.S.
4.4 Product Category Enumeration
4.4.1 Ketamine
4.4.2 Other Brands
4.5 Market Share, 2010–2014
4.5.1 Market Share, By Key Product
4.5.2 Market Share, By Key Player

5 Product Analysis (Page No. – 35)
5.1 Anesthesia Drugs Market Segmentation in the U.S.
5.1.1 General Anesthesia Drugs Market Segmentation
5.2 U.S.: Market Share, General Anesthetics, 2010–2014
5.2.1 Major Brands/Molecules
5.2.1.1 Propofol
5.2.1.2 Benzodiazepines
5.2.1.3 Methohexital Sodium
5.3 Competition in the U.S.
5.3.1 Key Competitors
5.3.2 Price
5.3.3 Major Brands
5.4 Local Sales Price
5.4.1 Manufacturer Price of Ketamine
5.5 Potential Buyers in the U.S.
5.5.1 Potential Buyers, By State

6 U.S. General Anesthesia Drugs Market: Key Information (Page No. – 50)
6.1 Import & Export Systems in U.S.
6.1.1 Import of Controlled Substances
6.1.1.1 Shipment of Controlled Substances
6.1.1.2 Applicants for Import and Export of Controlled Substances
6.1.2 Export of Controlled Substances
6.1.2.1 Exception for Exportation for Special Scientific Purposes
6.1.3 Based on Tariffs
6.1.3.1 Custom Tariff for Import
6.1.4 Based on Transport
6.1.5 Customs Clearance
6.1.6 Non-Tariff Barriers
6.2 Top Related Exhibitions
6.3 Description of Potential Buyers

7 Strategic Recommendations for Entering the U.S. General Anesthesia Drugs Market (Page No. – 64)

8 Company Profiles (Page No. – 66)
8.1 Introduction
8.2 Abbott Laboratories
8.2.1 Business Overview
8.2.2 Abbott Laboratories: Company Snapshot
8.2.3 Product Offered
8.3 Astrazeneca PLC
8.3.1 Business Overview
8.3.2 Astrazeneca PLC: Company Snapshot
8.3.3 Product Offered
8.4 Baxter International Inc.
8.4.1 Business Overview
8.4.2 Baxter International Inc.: Company Snapshot
8.4.3 Products Offered
8.5 Hikma Pharmaceuticals PLC
8.5.1 Business Overview
8.5.2 Products Offered
8.5.3 Recent Development
8.6 Mylan N.V.
8.6.1 Business Overview
8.6.2 Mylan N.V.: Company Snapshot
8.6.3 Product Offered
8.7 Eisai Co., Ltd.
8.7.1 Business Overview
8.7.2 Eisai Co., Ltd.: Company Snapshot
8.7.3 Products Offered
8.8 Fresenius Se & Co. Kgaa
8.8.1 Business Overview
8.8.2 Fresenius SE & Co. KGAA: Company Snapshot
8.8.3 Product Offered
8.8.4 Recent Developments
8.9 Hospira, Inc.
8.9.1 Business Overview
8.9.2 Product Offered
8.10 Par Pharmaceutical Companies, Inc.
8.10.1 Business Overview
8.10.2 Par Pharmaceutical Companies, Inc.: Company Snapshot
8.10.3 Products Offered
8.10.4 Recent Development

9 Appendix (Page No. – 79)
9.1 Regulations for Controlled Substances in the U.S.

Table of Contents (42 Tables)

Table 1 U.S.: Ketamine Market Size, By Distribution Channel, 2010–2014 (USD Million)
Table 2 U.S.: Ketamine Market Size, By Distribution Channel, 2015–2020 (USD Million)
Table 3 U.S.: Ketamine Market Size, By Manufacturer, 2010–2014 (USD Million)
Table 4 U.S.: Ketamine Market Size, By Manufacturer, 2010–2014 (Kilogram)
Table 5 U.S.: Ketamine Market Size, By Manufacturer, 2015–2020 (USD Million)
Table 6 U.S.: Ketamine Market Size, By Manufacturer, 2015–2020 (Kilogram)
Table 7 U.S.: Ketamine Market Size, By GPO, 2010–2014 (USD Million)
Table 8 U.S.: Ketamine Market Size, By GPO, 2010–2014 (Kilogram)
Table 9 U.S. Ketamine Market Size, By GPO, 2015–2020 (USD Million)
Table 10 U.S.: Ketamine Market Size, By GPO, 2015–2020 (Kilogram)
Table 11 U.S.: Ketamine Market Size, By Distributor, 2010–2014 (USD Million)
Table 12 U.S.: Ketamine Market Size, By Distributor, 2010–2014 (Kilogram)
Table 13 U.S.: Ketamine Market Size, By Distributor, 2015–2020 (USD Million)
Table 14 U.S.: Ketamine Market Size, By Distributor, 2015–2020 (Kilogram)
Table 15 Anesthesia Drugs Market Size, By Type, 2010-2014 (USD Million)
Table 16 Anesthesia Drugs Market Size, By Type, 2015-2020 (USD Million)
Table 17 U.S. Anesthesia Drugs Market Size, By Type, 2010–2014 (USD Million)
Table 18 U.S. Anesthesia Drugs Market Size, By Type, 2015–2020 (USD Million)
Table 19 U.S. General Anesthesia Drugs Market Size, By Type, 2010–2014 (USD Million)
Table 20 Ketamine: Major Competitor Brands & Molecules
Table 21 U.S. General Intravenous Anesthesia Drugs Market Size, By Molecule, 2010–2014 (USD Million)
Table 22 U.S. General Intravenous Anesthesia Drugs Market Size, By Molecule, 2015–2020 (USD Million)
Table 23 Ketamine: Price, 2012 (USD)
Table 24 Methohexital Sodium Price, 2012 (USD)
Table 25 Fospropofol Disodium Price, 2012 (USD)
Table 26 Pentobarbital Sodium Price, 2012 (USD)
Table 27 Propofol Price, 2012 (USD)
Table 28 Midazolam Price, 2012 (USD)
Table 29 Etomidate Sodium Price, 2012 (USD)
Table 30 Total Per Study Cost of Clinical Trials, By Phase, (USD Million)
Table 31 Ketamine Price, 2012 (USD)
Table 32 General Intravenous Anesthesia Drugs: Usage Trends
Table 33 U.S.: Top Abused Prescription Drugs, 2013
Table 34 Manufacturer Price of Ketamine, 2012
Table 35 Group Purchasing Organizations, By State
Table 36 Distributors, By State
Table 37 Harmonized Tariff Schedule for Anesthesia Drugs
Table 38 Anesthesia Molecules: Chemical Abstracts Services (CAS) Numbers
Table 39 Regulatory Requirements for Controlled Substances
Table 40 Anesthesia Exhibitions
Table 41 Potential Group Purchasing Organizations
Table 42 Potential Distributors


List of Figures (28 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation Methodology : Bottom-Up Approach
Figure 3 Market Size Estimation Methodology : Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Country/Region
Figure 5 Data Triangulation Methodology
Figure 6 U.S. Ketamine Market Size, 2015 vs 2020 (USD Million)
Figure 7 U.S. Ketamine Market Size, By Item, 2015 vs 2020 (USD Million)
Figure 8 U.S. Ketamine Market Size, 2010–2014 (USD Million)
Figure 9 U.S. Ketamine Market Size, 2015–2020 (USD Million)
Figure 10 Distribution Structure
Figure 11 U.S. Ketamine Market Share, By GPO (2014)
Figure 12 U.S. Ketamine Market Share, By Distributor (2014)
Figure 13 U.S. Ketamine Market Size, By Brand, 2010–2014 (USD Million)
Figure 14 U.S. Ketamine Market Share, By Key Product, 2010 vs 2014
Figure 15 U.S. Ketamine Market Share, By Key Player, 2010 vs 2014
Figure 16 Anesthetics Market Segmentation
Figure 17 Location Quotient of Anesthesia Specialists in the U.S., By State (May 2014)
Figure 18 Anesthesia Landscape
Figure 19 General Anesthetics Landscape
Figure 20 Market Size, By Molecule, 2010 & 2020 (USD Million)
Figure 21 Properties of Intravenous Anesthesia Drugs
Figure 22 General Intravenous Anesthesia Drugs Market Size, By Molecule, 2014 (USD Million)
Figure 23 Custom Clearance Procedure for Import of Controlled Substances in the U.S.
Figure 24 Export Customs Clearance Procedure for Controlled Substances in the U.S.
Figure 25 Business Strategy
Figure 26 Geographic Revenue Mix of the Top Three Market Players
Figure 27 Hikma Pharmaceuticals PLC: Company Snapshot
Figure 28 Hospira, Inc.: Company Snapshot

【レポートのキーワード】

全身麻酔薬、プロポフォール、ベンゾジアゼピン、ケタミン、メトヘキシタールナトリウム、医薬品、治療

★調査レポート[アメリカの全身麻酔薬市場:プロポフォール、ベンゾジアゼピン、ケタミン、メトヘキシタールナトリウム] ( U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020 / MAM-PH-1174) 販売に関する免責事項
[アメリカの全身麻酔薬市場:プロポフォール、ベンゾジアゼピン、ケタミン、メトヘキシタールナトリウム] ( U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020 / MAM-PH-1174) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆